ASA404: update on drug development

Bibliography

• Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-8
   PubMed Web of Science ®Google Scholar
• Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 1990;9:267-82
   PubMed Web of Science ®Google Scholar
• Bloemendal HJ, Logtenberg T, Voest EE. New strategies in anti-vascular cancer therapy. Eur J Clin Invest 1999;29:802-9
   PubMed Web of Science ®Google Scholar
• Baguley BC, Calveley SB, Crowe KK, et al. Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor alpha on colon 38 tumours in mice. Eur J Cancer Clin Oncol 1989;25:263-9
   PubMedGoogle Scholar
• Smith GP, Calveley SB, Smith MJ, et al. Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours. Eur J Cancer Clin Oncol 1987;23:1209-11
   PubMedGoogle Scholar
• Corbett TH, Bissery MC, Wozniak A, et al. Activity of flavone acetic acid (NSC-347512) against solid tumors of mice. Invest New Drugs 1986;4:207-20
   PubMed Web of Science ®Google Scholar
• Kerr DJ, Kaye SB. Flavone acetic acid – preclinical and clinical activity. Eur J Cancer Clin Oncol 1989;25:1271-2
   PubMedGoogle Scholar
• Rewcastle GW, Atwell GJ, Li ZA, et al. Potential antitumor agents: 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem 1991;34:217-22
   PubMed Web of Science ®Google Scholar
• Bibby MC, Double JA, Loadman PM, et al. Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy. J Natl Cancer Inst 1989;81:216-20
   PubMed Web of Science ®Google Scholar
• Zwi LJ, Baguley BC, Gavin JB, et al. Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. J Natl Cancer Inst 1989;81:1005-13
   PubMed Web of Science ®Google Scholar
• Ching LM, Zwain S, Baguley BC. Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer 2004;90:906-10
   PubMed Web of Science ®Google Scholar
• Thomsen LL, Baguley BC, Wilson WR. Nitric oxide: its production in host-cell-infiltrated EMT6 spheroids and its role in tumour cell killing by flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 1992;31:151-5
   PubMed Web of Science ®Google Scholar
• Roberts ZJ, Ching LM, Vogel SN. IFN-beta-dependent inhibition of tumor growth by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). J Interferon Cytokine Res 2008;28:133-9
   PubMed Web of Science ®Google Scholar
• Zwi LJ, Baguley BC, Gavin JB, et al. Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol Res 1994;6:79-85
   PubMed Web of Science ®Google Scholar
• Zwi LJ, Baguley BC, Gavin JB, et al. Necrosis in non-tumour tissues caused by flavone acetic acid and 5,6-dimethyl xanthenone acetic acid. Br J Cancer 1990;62:932-4
   PubMed Web of Science ®Google Scholar
• Ching LM, Joseph WR, Crosier KE, et al. Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Res 1994;54:870-2
   PubMed Web of Science ®Google Scholar
• Philpott M, Joseph WR, Crosier KE, et al. Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Br J Cancer 1997;76:1586-91
   PubMed Web of Science ®Google Scholar
• Siemann D, Chaplin DJ. An update on the clinical development of drugs to disable tumor vasculature. Expert Opin Drug Discov 2007;2:1357-67
   PubMed Web of Science ®Google Scholar
• Baguley BC. Antivascular therapy of cancer: DMXAA. Lancet Oncol 2003;4:141-8
   PubMed Web of Science ®Google Scholar
• Zhao L, Ching LM, Kestell P, et al. The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br J Cancer 2002;87:465-70
   PubMed Web of Science ®Google Scholar
• Ching LM, Cao Z, Kieda C, et al. Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 2002;86:1937-42
   PubMed Web of Science ®Google Scholar
• Lash CJ, Li AE, Rutland M, et al. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 1998;78:439-45
   PubMed Web of Science ®Google Scholar
• Thomsen LL, Ching LM, Zhuang L, et al. Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. Cancer Res 1991;51:77-81
   PubMed Web of Science ®Google Scholar
• Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 1999;19:189-95
   PubMed Web of Science ®Google Scholar
• Chaplin DJ, Dougherty GJ. Tumour vasculature as a target for cancer therapy. Br J Cancer 1999;80(Suppl 1):57-64
   PubMed Web of Science ®Google Scholar
• Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415-27
   PubMed Web of Science ®Google Scholar
• Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005;5:423-35
   PubMed Web of Science ®Google Scholar
• Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004;100:2491-9
   PubMed Web of Science ®Google Scholar
• Gaya A, Violet J, Dancey G, et al. A phase I/II trial of radioimmunotherapy with 131Iodine labelled A5B7 anti-CEA antibody (131I-A5B7) in combination with combretastatin-A4-phosphate (CA4P) in advanced gastrointestinal carcinomas. J Clin Oncol 2008;26 (abstract 14517)
   Google Scholar
• McKeage M, Kelland L. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA): clinical potential in combination with taxane-based chemotherapy. Am J Cancer 2006;5:155-62
   Google Scholar
• Siim BG, Lee AE, Shalal-Zwain S, et al. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 2003;51:43-52
   PubMed Web of Science ®Google Scholar
• Jameson MB, Baguley BC, Kestell P, et al. Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial. Cancer Chemother Pharmacol 2007;59:681-7
   PubMed Web of Science ®Google Scholar
• Rustin GJ, Bradley C, Galbraith S, et al. 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br J Cancer 2003;88:1160-7
   PubMed Web of Science ®Google Scholar
• Jameson MB, Thompson PI, Baguley BC, et al. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 2003;88:1844-50
   PubMed Web of Science ®Google Scholar
• McKeage MJ, Fong P, Jeffery M, et al. 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. Clin Cancer Res 2006;12:1776-84
   PubMed Web of Science ®Google Scholar
• Galbraith SM, Rustin GJ, Lodge MA, et al. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 2002;20:3826-40
   PubMed Web of Science ®Google Scholar
• McKeage M. Phase I/II study of DMXAA combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC) [abstract 7102]. J Clin Oncol 2006;24
   Google Scholar
• McKeage M, von Pawel J. Phase II study of DMXAA (AS1404) 1800 mg/m2 combined with carboplatin and paclitaxel in non-small cell lung cancer. Poster presentation at World Conference on Lung Cancer, September 2007, Seoul, South Korea. J Thorac Oncol 2007;2:s728
   Google Scholar
• Rosenthal MPR. Randomized phase II study of docetaxel with or without DMXAA (AS1404) in hormone-refractory metastatic prostate cancer (HRMPC) [abstract 219]. American Society of Clinical Oncology Prostate Cancer Symposium; February 2007; Orlando, USA
   Google Scholar
• Pili RRM. Addition of DMXAA (ASA404) to docetaxel in patients with hormone-refractory metastatic prostate cancer (HRMPC): update from a randomized, phase II study [abstract 5007]. J Clin Oncol 2008;26(Suppl)
   Google Scholar
• Gabra H. Phase II study of DMXAA combined with carboplatin and paclitaxel in recurrent ovarian cancer [abstract 5032]. J Clin Oncol 2006;24(Suppl)
   Google Scholar
• G Edwards. Antisoma announces further data from ASA404 ovarian cancer trial. Available from: http://www.antisoma.com/asm/media/press/pr2007/2007-07-12/
   Google Scholar
• Gould S, Westwood FR, Curwen JO, et al. Effect of pretreatment with atenolol and nifedipine on ZD6126-induced cardiac toxicity in rats. J Natl Cancer Inst 2007;99:1724-8
   PubMed Web of Science ®Google Scholar
• Nathan P, Judson I, Padhani A, et al. A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors [abstract 3550]. J Clin Oncol 2008;26(Suppl)
   PubMedGoogle Scholar